

Papers related to BreastScreen Norway, published in peer-reviewed journals by October, 2023

This list is not exhaustive.

1. Thy JE, Larsen M, Vigeland E, Koch H, Hovda T, Hofvind S. Early performance measures following regular versus irregular screening attendance in the population-based screening program for breast cancer in Norway. *J Med Screen.* 2023;0(0):9691413231199583.
2. Pedersen K, Hovda T. To think it, wish it, even want it-but do it! Quality control measures in mammography image interpretation: radiologists' attitudes and preferences vs perceived obstacles and limitations. *Eur Radiol.* 2023;33(11):8100-2.
3. Moshina N, Sagstad S, Holen AS, Backmann HA, Westermann LC, Hofvind S. Experience of pain during mammographic screening by three different compression paddles. *Radiography (London, England : 1995).* 2023;29(5):903-10.
4. Zhang L, Mosquera I, Lucas E, Rol ML, Carvalho AL, Basu P, CanScreen c. CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs. *Nat Med.* 2023;29(5):1135-45.
5. Martiniussen MA, Larsen M, Larsen ASF, Hovda T, Koch HW, Bjornerud A, Hofvind S. Norwegian radiologists' expectations of artificial intelligence in mammographic screening - A cross-sectional survey. *Eur J Radiol.* 2023;167:111061.
6. Louro J, Roman M, Moshina N, Olstad CF, Larsen M, Sagstad S, et al. Personalized Breast Cancer Screening: A Risk Prediction Model Based on Women Attending BreastScreen Norway. *Cancers (Basel).* 2023;15(18):4517.
7. Larsen M, Olstad CF, Koch HW, Martiniussen MA, Hoff SR, Lund-Hanssen H, et al. AI Risk Score on Screening Mammograms Preceding Breast Cancer Diagnosis. *Radiology.* 2023;309(1):e230989.
8. Hovda T, Larsen M, Romundstad L, Sahlberg KK, Hofvind S. Breast cancer missed at screening; hindsight or mistakes? *Eur J Radiol.* 2023;165:110913.
9. Hofvind S, Iqbal N, Thy JE, Mangerud G, Bhargava S, Zackrisson S, Berstad P. Effect of invitation letter in language of origin on screening attendance: randomised controlled trial in BreastScreen Norway. *BMJ.* 2023;382:e075465.
10. Holen AS, Bergan MB, Lee CI, Zackrisson S, Moshina N, Aase HS, et al. Early screening outcomes before, during, and after a randomized controlled trial with digital breast tomosynthesis. *Eur J Radiol.* 2023;167:111069.
11. Eijkelboom AH, Larsen M, Siesling S, Nygard JF, Hofvind S, de Munck L. Prolonged screening interval due to the COVID-19 pandemic and its association with tumor characteristics and treatment; a register-based study from BreastScreen Norway. *Preventive medicine.* 2023;175:107723.
12. Eijkelboom AH, de Munck L, Larsen M, Bijlsma MJ, Tjan-Heijnen VCG, van Gils CH, et al. Impact of the COVID-19 pandemic on breast cancer incidence and tumor stage in the Netherlands and Norway: A population-based study. *Cancer Epidemiol.* 2023;87:102481.
13. Larsen M, Lynge E, Lee CI, Lång K, Hofvind S. Mammographic density and interval cancers in mammographic screening: Moving towards more personalized screening. *The Breast.* 2023;69:306-11.
14. Koch HW, Larsen M, Bartsch H, Kurz KD, Hofvind S. Artificial intelligence in BreastScreen Norway: a retrospective analysis of a cancer-enriched sample including 1254 breast cancer cases. *European Radiology.* 2023.
15. Skjerven HK, Myklebust EM, Korvald C, Porojnicu AC, Kaaresen R, Hofvind S, et al. Oncological outcomes after simple and skin-sparing mastectomy of ductal carcinoma in situ: A register-based cohort study of 576 Norwegian women. *Eur J Surg Oncol.* 2023;49(3):575-82.
16. Løfling L, Støer NC, Nafisi S, Ursin G, Hofvind S, Botteri E. Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women. *Eur J Epidemiol.* 2023.
17. Thy JE, Vigeland E, Larsen M, Hofvind S. Participation and cancer detection after reminders versus ordinary invitations in BreastScreen Norway. *J Med Screen.* 2022;29(3):178-84.
18. Thy JE, Bhargava S, Larsen M, Akslen LA, Hofvind S. Early screening outcomes among non-immigrants and immigrants targeted by BreastScreen Norway, 2010-2019. *Scand J Public Health.* 2022;0(0):14034948221078701.
19. Robsahm TE, Sagstad S, Thy JE, Hofvind S. Sociodemographic factors, health indicators and lifestyle factors among participants in BreastScreen Norway 2006-2016—a cohort profile. *Norsk Epidemiologi.* 2022;30(1-2).

20. Moshina N, Bjornson EW, Holen AS, Larsen M, Hansestad B, Tosdal L, et al. Standardised or individualised X-ray tube angle for mediolateral oblique projection in digital mammography? *Radiography (London, England : 1995)*. 2022;28(3):772-8.
21. Moger TA, Holen A, Hanestad B, Hofvind S. Costs and Effects of Implementing Digital Tomosynthesis in a Population-Based Breast Cancer Screening Program: Predictions Using Results from the To-Be Trial in Norway. *Pharmacoecon Open*. 2022;6(4):495-507.
22. Martiniussen MA, Sagstad S, Larsen M, Larsen ASF, Hovda T, Lee CI, et al. Screen-detected and interval breast cancer after concordant and discordant interpretations in a population based screening program using independent double reading. *Eur Radiol*. 2022;32(9):5974-85.
23. Libesman S, Zackrisson S, Hofvind S, Seidler AL, Bernardi D, Lang K, et al. An individual participant data meta-analysis of breast cancer detection and recall rates for digital breast tomosynthesis versus digital mammography population screening. *Clin Breast Cancer*. 2022;22(5):e647-e54.
24. Larsen M, Aglen CF, Lee CI, Hoff SR, Lund-Hanssen H, Lang K, et al. Artificial Intelligence Evaluation of 122 969 Mammography Examinations from a Population-based Screening Program. *Radiology*. 2022;303(3):502-11.
25. Larsen M, Aglen CF, Hoff SR, Lund-Hanssen H, Hofvind S. Possible strategies for use of artificial intelligence in screen-reading of mammograms, based on retrospective data from 122,969 screening examinations. *Eur Radiol*. 2022;32(12):8238-46.
26. Ankill J, Aure MR, Bjørklund S, Langberg S, Kristensen VN, Vitelli V, et al. Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer. *NAR Cancer*. 2022;4(1):zcac008.
27. Skjerven HK, Danielsen AS, Schlichting E, Sahlberg KK, Hofvind S. Treatment of Ductal Carcinoma in situ: A Register-Based Study of Norwegian Women Diagnosed between 1995 and 2018. *Breast Care (Basel)*. 2022 Oct;17(5):486-494.
28. Holen AS, Mangerud G, Hofvind S. Mammografiprogrammet—tidligere, i dag og i fremtiden. *Norsk Epidemiologi*. 2022;30(1-2).
29. Hofvind S, Mangerud G, Holen AS, Ursin G. Overdiagnostikk—eksemplifisert ved mammografiscreening. *Norsk Epidemiologi*. 2022;30(1-2).
30. Anderson AW, Marinovich ML, Houssami N, Lowry KP, Elmore JG, Buist DSM, et al. Independent External Validation of Artificial Intelligence Algorithms for Automated Interpretation of Screening Mammography: A Systematic Review. *J Am Coll Radiol*. 2022;19(2 Pt A):259-73.
31. Hofvind S, Lee CI. A Warning about Warning Signals for Interpreting Mammograms. *Radiology*. 2022;302(2):284-5.
32. Bhargava S, Czapka E, Hofvind S, Kristiansen M, Diaz E, Berstad P. Polish immigrants' access to colorectal cancer screening in Norway - a qualitative study. *BMC Health Serv Res*. 2022;22(1):1332.
33. Aase HS, Danielsen AS, Hoff SR, Holen AS, Haldorsen IS, Hovda T, et al. Mammographic features and screening outcome in a randomized controlled trial comparing digital breast tomosynthesis and digital mammography. *Eur J Radiol*. 2021:109753.
34. Waade GG, Danielsen AS, Holen AS, Larsen M, Hanestad B, Hopland N-M, et al. Assessment of breast positioning criteria in mammographic screening: Agreement between artificial intelligence software and radiographers. *Journal of Medical Screening*. 2021.
35. Tsuruda KM, Larsen M, Roman M, Hofvind S. Cumulative risk of a false-positive screening result: A retrospective cohort study using empirical data from 10 biennial screening rounds in BreastScreen Norway. *Cancer*. 2021.
36. Tsuruda K, Veierød M, Houssami N, Waade G, Mangerud G, Hofvind S. Women's conceptual knowledge about breast cancer screening and overdiagnosis in Norway: a cross-sectional study. *BMJ Open*. 2021;11(12):e052121.
37. Moshina N, Larsen M, Holen AS, Waade GG, Aase HS, Hofvind S. Digital breast tomosynthesis in a population based mammographic screening program: Breast compression and early performance measures. *Eur J Radiol*. 2021;139:109665.
38. Moshina N, Falk RS, Hofvind S. Long-term quality of life among breast cancer survivors eligible for screening at diagnosis: a systematic review and meta-analysis. *Public Health*. 2021;199:65-76.
39. Moshina N, Falk RS, Botteri E, Larsen M, Akslen LA, Cairns JA, et al. Quality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway. *Qual Life Res*. 2021.
40. Lång K, Hofvind S, Rodríguez-Ruiz A, Andersson I. Can artificial intelligence reduce the interval cancer rate in mammography screening? *Eur Radiol*. 2021.
41. Lilleborge M, Falk RS, Hovda T, Holmen MM, Ursin G, Hofvind S. Patterns of aggressiveness: risk of progression to invasive breast cancer by mammographic features of calcifications in screen-detected ductal carcinoma in situ. *Acta radiologica (Stockholm, Sweden : 1987)*. 2021:2841851211006319.

42. Johansson ALV, Trewin CB, Fredriksson I, Reinertsen KV, Russnes H, Ursin G. In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study. *Breast Cancer Res.* 2021;23(1):17.
43. Hovda T, Tsuruda K, Hoff SR, Sahlberg KK, Hofvind S. Radiological review of prior screening mammograms of screen-detected breast cancer. *Eur Radiol.* 2021;31(4):2568-79.
44. Hovda T, Hoff SR, Larsen M, Romundstad L, Sahlberg KK, Hofvind S. True and Missed Interval Cancer in Organized Mammographic Screening: A Retrospective Review Study of Diagnostic and Prior Screening Mammograms. *Acad Radiol.* 2021.
45. Houssami N, Zackrisson S, Blazek K, Hunter K, Bernardi D, Lang K, et al. Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population screening. *Eur J Cancer.* 2021;148:14-23.
46. Houssami N, Hofvind S, Soerensen AL, Robledo KP, Hunter K, Bernardi D, et al. Interval breast cancer rates for digital breast tomosynthesis versus digital mammography population screening: An individual participant data meta-analysis. *EClinicalMedicine.* 2021;34:100804.
47. Holen ÅS, Larsen M, Moshina N, Wåade GG, Sechopoulos I, Hanestad B, et al. Visualization of the Nipple in Profile: Does It Really Affect Selected Outcomes in Organized Mammographic Screening? *Journal of Breast Imaging.* 2021;3(4):427-37.
48. Hofvind S, Moshina N, Holen AS, Danielsen AS, Lee CI, Houssami N, et al. Interval and Subsequent Round Breast Cancer in a Randomized Controlled Trial Comparing Digital Breast Tomosynthesis and Digital Mammography Screening. *Radiology.* 2021;300(1):66-76.
49. Hofvind S, Knutsvik G, Holen AS, Tsuruda KM, Akslen LA. Detection and significance of small and low proliferation breast cancer. *J Med Screen.* 2021:9691413211023970.
50. Pinto MC, Rodriguez-Ruiz A, Pedersen K, Hofvind S, Wicklein J, Kappler S, Mann RM, Sechopoulos I. Impact of Artificial Intelligence Decision Support Using Deep Learning on Breast Cancer Screening Interpretation with Single-View Wide-Angle Digital Breast Tomosynthesis. *Radiology.* 2021 Sep;300(3):529-536.
51. Gottschalk MS, Eskild A, Hofvind S, Bjelland EK. The relation of number of childbirths with age at natural menopause: a population study of 310 147 women in Norway. *Hum Reprod.* 2021.
52. Bhargava S, Mangerud G, Hofvind S. Attendance in BreastScreen Norway among immigrant and Norwegian-born women. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række.* 2021;141(2).
53. Backmann HA, Larsen M, Danielsen AS, Hofvind S. Does it matter for the radiologists' performance whether they read short or long batches in organized mammographic screening? *Eur Radiol.* 2021.
54. Lilleborge M, Falk RS, Sørli T, Ursin G, Hofvind S. Can breast cancer be stopped? Modifiable risk factors of breast cancer among women with a prior benign or premalignant lesion. *Int J Cancer.* 2021 Sep 15;149(6):1247-1256.
55. Weedon-Fekjaer H, Li X, Lee S. Estimating the natural progression of non-invasive ductal carcinoma in situ breast cancer lesions using screening data. *J Med Screen.* 2020:969141320945736.
56. Tsuruda KM, Hovda T, Bhargava S, Veierød MB, Hofvind S. Survival among women diagnosed with screen-detected or interval breast cancer classified as true, minimal signs, or missed through an informed radiological review. *Eur Radiol.* 2020.
57. Tsuruda KM, Hofvind S, Akslen LA, Hoff SR, Veierød MB. Terminal digit preference: a source of measurement error in breast cancer diameter reporting. *Acta Oncol.* 2020;59(3):260-7.
58. Sonden ECB, Sebuodegard S, Korvald C, Lomo J, Schlichting E, Brandal SHB, et al. Kosmetiske brystimplantater og brystkreft. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række.* 2020;140(3).
59. Skaane P. Brystimplantater til besvær. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række.* 2020;140(3).
60. Skjerven HK, Danielsen AS, Schlichting E, Sahlberg KK, Hofvind S. Surgical treatment of breast cancer in Norway 2003-2018. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række.* 2020;140(15).
61. Muratov S, Canelo-Aybar C, Tarride JE, Alonso-Coello P, Dimitrova N, Borisch B, et al. Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators. *BMC Cancer.* 2020;20(1):795.
62. Moshina N, Aase HS, Danielsen AS, Haldorsen IS, Lee CI, Zackrisson S, et al. Comparing Screening Outcomes for Digital Breast Tomosynthesis and Digital Mammography by Automated Breast Density in a Randomized Controlled Trial: Results from the To-Be Trial. *Radiology.* 2020;297(3):522-31.
63. Moshina N, Danielsen AS, Hølen ÅS, Hanestad B, Stephansen E, Pedersen IH, et al. Self-reported Pain Associated With Screening With Digital Breast Tomosynthesis. *Journal of Breast Imaging.* 2020.

64. Lilleborge M, Falk RS, Hofvind S. Number of prior negative screening outcomes does not influence future risk of breast cancer. *Eur J Epidemiol.* 2020;35(6):549-56.
65. Larsen M, Moshina N, Sagstad S, Hofvind S. Factors associated with attendance and attendance patterns in a population-based mammographic screening program. *Journal of Medical Screening.* 2020.
66. Larsen M, Lilleborge M, Vigeland E, Hofvind S. Self-reported symptoms among participants in a population-based screening program. *Breast.* 2020;54:56-61.
67. Holen A, Sebuodegard S, Waade GG, Aase H, Hopland NM, Pedersen K, et al. Screening at stationary versus mobile units in BreastScreen Norway. *J Med Screen.* 2020;27(1):31-9.
68. Gottschalk MS, Eskild A, Hofvind S, Gran JM, Bjelland EK. Temporal trends in age at menarche and age at menopause: a population study of 312 656 women in Norway. *Hum Reprod.* 2020;35(2):464-71.
69. Bergholtz H, Lien TG, Swanson DM, Frigessi A, Oslo Breast Cancer Research C, Daidone MG, et al. Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions. *NPJ Breast Cancer.* 2020;6:26.
70. Baldeh T, Saz-Parkinson Z, Muti P, Santesso N, Morgano GP, Wiercioch W, et al. Development and use of health outcome descriptors: a guideline development case study. *Health Qual Life Outcomes.* 2020;18(1):167.
71. Backmann HA, Larsen M, Danielsen AS, Hofvind S. Time of day and mammographic reader performance in a population-based breast cancer screening programme. *J Med Screen.* 2020:969141320953206.
72. Waade GG, Holen A, Sebuodegard S, Aase H, Pedersen K, Hanestad B, et al. Breast compression parameters among women screened with standard digital mammography and digital breast tomosynthesis in a randomized controlled trial. *Acta radiologica (Stockholm, Sweden : 1987).* 2019;284185119863989.
73. Tsuruda KM, Bhargava S, Akslén LA, Bjørndal H, Hofvind S. Forløpstider i Mammografi-programmet før og etter innføring av pakkeforløp for brystkreft. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række.* 2019;139(12).
74. Skaane P, Bandos AI, Niklason LT, Sebuodegard S, Osteras BH, Gullien R, et al. Digital Mammography versus Digital Mammography Plus Tomosynthesis in Breast Cancer Screening: The Oslo Tomosynthesis Screening Trial. *Radiology.* 2019;291(1):23-30.
75. Sebuodegard S, Botteri E, Hofvind S. Breast cancer mortality after implementation of organized population-based breast cancer screening in Norway. *J Natl Cancer Inst.* 2019.
76. Schünemann HJ, Lerda D, Quinn C, Follmann M, Alonso-Coello P, Rossi PG, et al. Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines. *Annals of internal medicine.* 2019.
77. Schünemann HJ, Lerda D, Dimitrova N, Alonso-Coello P, Grawingholt A, Quinn C, et al. Methods for Development of the European Commission Initiative on Breast Cancer Guidelines: Recommendations in the Era of Guideline Transparency. *Annals of internal medicine.* 2019.
78. Rosenberg RD, Seidenwurm D. Optimizing Breast Cancer Screening Programs: Experience and Structures. *Radiology.* 2019;292(2):297-8.
79. Roman M, Hofvind S, von Euler-Chelpin M, Castells X. Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: joint analysis of three national cohorts. *Br J Cancer.* 2019;120(2):269-75.
80. Ponti A, Ronco G, Lynge E, Tomatis M, Anttila A, Ascunce N, et al. Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: evidence from an international multi-centre study. *Breast Cancer Res Treat.* 2019;177(3):761-5.
81. Osteras BH, Martinsen ACT, Gullien R, Skaane P. Digital Mammography versus Breast Tomosynthesis: Impact of Breast Density on Diagnostic Performance in Population-based Screening. *Radiology.* 2019;293(1):60-8.
82. Moshina N, Sebuodegard S, Evensen KT, Hantho C, Iden KA, Hofvind S. Breast compression and experienced pain during mammography by use of three different compression paddles. *Eur J Radiol.* 2019;115:59-65.
83. Moshina N, Sagstad S, Sebuødegård S, Waade GG, Gran E, Music J, et al. Breast compression and reported pain during mammographic screening. *Radiography.* 2019.
84. Moger TA, Swanson JO, Holen AS, Hanestad B, Hofvind S. Cost differences between digital tomosynthesis and standard digital mammography in a breast cancer screening programme: results from the To-Be trial in Norway. *The European journal of health economics : HEPAC : health economics in prevention and care.* 2019.
85. Lilleborge M, Falk RS, Russnes H, Sauer T, Ursin G, Hofvind S. Risk of breast cancer by prior screening results among women participating in BreastScreen Norway. *Cancer.* 2019.
86. Hovda T, Holen AS, Lang K, Albertsen JL, Bjørndal H, Brandal SHB, et al. Interval and Consecutive Round Breast Cancer after Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Standard 2D Digital Mammography in BreastScreen Norway. *Radiology.* 2019:191337.

87. Hovda T, Brandal SHB, Sebuodegard S, Holen AS, Bjorndal H, Skaane P, et al. Screening outcome for consecutive examinations with digital breast tomosynthesis versus standard digital mammography in a population-based screening program. *Eur Radiol.* 2019.
88. Hofvind S, Holen ÅS, Aase HS, Houssami N, Sebuødegård S, Moger TA, et al. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial. *The Lancet Oncology.* 2019.
89. Hoff SR, Myklebust TA, Lee CI, Hofvind S. Influence of Mammography Volume on Radiologists' Performance: Results from BreastScreen Norway. *Radiology.* 2019;292(2):289-96.
90. Bjelland EK, Gran JM, Hofvind S, Eskild A. The association of birthweight with age at natural menopause: a population study of women in Norway. *Int J Epidemiol.* 2019.
91. Bhargava S, Hofvind S, Moen K. Gender, letters, relatives, and God: mediating actors in mammographic screening among Pakistani women in Norway. *Acta Radiol Open.* 2019;8(9):2058460119875015.
92. Bhargava S, Akslen LA, Bukholm IRK, Hofvind S. Performance measures among non-immigrants and immigrants attending BreastScreen Norway: a population-based screening programme. *Eur Radiol.* 2019.
93. Aase HS, Holen AS, Pedersen K, Houssami N, Haldorsen IS, Sebuodegard S, et al. A randomized controlled trial of digital breast tomosynthesis versus digital mammography in population-based screening in Bergen: interim analysis of performance indicators from the To-Be trial. *Eur Radiol.* 2018.
94. Waade GG, Sebuodegard S, Hogg P, Hofvind S. Breast compression across consecutive examinations among females participating in BreastScreen Norway. *Brit J Radiol.* 2018;91(1090).
95. Westvik AS, Weedon-Fekjaer H, Maehlen J, Liestol K. Evaluating different breast tumor progression models using screening data. *BMC Cancer.* 2018;18(1):209.
96. Tsuruda KM, Sagstad S, Sebuodegard S, Hofvind S. Validity and reliability of self-reported health indicators among women attending organized mammographic screening. *Scand J Public Health.* 2018:1403494817749393.
97. Solbjør M, Forsmo S, Skolbekken JA, Siersma V, Brodersen J. Psychosocial consequences among women with false-positive results after mammography screening in Norway. *Scand J Prim Health Care.* 2018;36(4):380-9.
98. Skaane P, Sebuodegard S, Bandos AI, Gur D, Osteras BH, Gullien R, et al. Performance of breast cancer screening using digital breast tomosynthesis: results from the prospective population-based Oslo Tomosynthesis Screening Trial. *Breast Cancer Research and Treatment.* 2018;169(3):489-96.
99. Sandvei MS, Vatten L, Bjelland EK, Eskild A, Hofvind S, Ursin G, et al. Menopausal hormone therapy and breast cancer risk: effect modification by body mass through life. *Eur J Epidemiol.* 2018.
100. Moshina N, Sebuødegård S, Holen ÅS, Waade GG, Tsuruda K, Hofvind S. The impact of compression force and pressure at prevalent screening on subsequent re-attendance in a national screening program. *Preventive medicine.* 2018;108:129-36.
101. Moshina N, Sebuodegard S, Lee CI, Akslen LA, Tsuruda KM, Elmore JG, et al. Automated Volumetric Analysis of Mammographic Density in a Screening Setting: Worse Outcomes for Women with Dense Breasts. *Radiology.* 2018;288(2):343-52.
102. Moshina N, Roman M, Waade GG, Sebuodegard S, Ursin G, Hofvind S. Breast compression parameters and mammographic density in the Norwegian Breast Cancer Screening Programme. *Eur Radiol.* 2018;28:1662-72.
103. Moshina N, Roman M, Sebuodegard S, Waade GG, Ursin G, Hofvind S. Comparison of subjective and fully automated methods for measuring mammographic density. *Acta radiologica (Stockholm, Sweden : 1987).* 2018;59(2):154-60.
104. Lilleborge M, Hofvind S, Sebuodegard S, Hauge R. Optimizing performance of BreastScreen Norway using value of information in graphical models. *Statistics in Medicine.* 2018;37(9):1531-49.
105. Le M, Hofvind S, Tsuruda K, Braaten T, Bhargava S. Lower attendance rates in BreastScreen Norway among immigrants across all levels of socio-demographic factors: a population-based study. *Journal of Public Health.* 2018.
106. Larsen IK, Myklebust TA, Johannesen TB, Moller B, Hofvind S. Stage-specific incidence and survival of breast cancer in Norway: The implications of changes in coding and classification practice. *Breast.* 2018;38:107-13.
107. Hofvind S, Sagstad S, Sebuodegard S, Chen Y, Roman M, Lee CI. Interval Breast Cancer Rates and Histopathologic Tumor Characteristics after False-Positive Findings at Mammography in a Population-based Screening Program. *Radiology.* 2018;287(1):58-67.
108. Hofvind S, Hovda T, Holen AS, Lee CI, Albertsen J, Bjorndal H, et al. Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Digital Mammography: Evaluation in a Population-based Screening Program. *Radiology.* 2018;287(3):787-94.

109. Hjerkind KV, Ellingjord-Dale M, Johansson ALV, Aase HS, Hoff SR, Hofvind S, et al. Volumetric Mammographic Density, Age-Related Decline, and Breast Cancer Risk Factors in a National Breast Cancer Screening Program. *Cancer Epidemiol Biomarkers Prev.* 2018;27(9):1065-74.
110. Bjelland EK, Hofvind S, Byberg L, Eskild A. The relation of age at menarche with age at natural menopause: a population study of 336 788 women in Norway. *Hum Reprod.* 2018 Jun 1;33(6):1149-1157.
111. Ellingjord-Dale M, Vos L, Vik Hjerkind K, Hjartaker A, Russnes HG, Tretli S, et al. Number of Risky Lifestyle Behaviors and Breast Cancer Risk. *JNCI Cancer Spectr.* 2018;2(3):pky030.
112. Broeders MJM, Allgood P, Duffy SW, Hofvind S, Nagtegaal ID, Paci E, et al. The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review. *BMC Cancer.* 2018;18(1):860.
113. Bhargava S, Tsuruda K, Moen K, Bukholm I, Hofvind S. Lower attendance rates in immigrant versus non-immigrant women in the Norwegian Breast Cancer Screening Programme. *J Med Screen.* 2018;25(3):155-61.
114. Bhargava S, Moen K, Qureshi SA, Hofvind S. Mammographic screening attendance among immigrant and minority women: a systematic review and meta-analysis. *Acta Radiologica.* 2018;59(11):1285-91.
115. Waade GG, Sanderud A, Hofvind S. Compression force and radiation dose in the Norwegian Breast Cancer Screening Program. *Eur J Radiol.* 2017;88:41-6.
116. Botteri E, Støer NC, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind S, Ursin G, Weiderpass E. Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role? *Int J Cancer.* 2017 Nov 1;141(9):1763-1770.
117. Waade GG, Moshina N, Sebuodegard S, Hogg P, Hofvind S. Compression forces used in the Norwegian Breast Cancer Screening Program. *Br J Radiol.* 2017;90(1071):20160770.
118. Waade GG, Hofvind S, Thompson JD, Highnam R, Hogg P. Development of a phantom to test fully automated breast density software - A work in progress. *Radiography (London, England : 1995).* 2017;23(1):e14-e9.
119. van Luijt PA, Heijnsdijk EA, van Ravesteyn NT, Hofvind S, de Koning HJ. Breast cancer incidence trends in Norway and estimates of overdiagnosis. *J Med Screen.* 2017;24(2):83-91.
120. van Luijt PA, Heijnsdijk EA, de Koning HJ. Cost-effectiveness of the Norwegian breast cancer screening program. *Int J Cancer.* 2017;140(4):833-40.
121. Botteri E, Støer NC, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind S, de Lange T, Bagnardi V, Ursin G, Weiderpass E. Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway. *BMJ Open.* 2017 Nov 15;7(11):e017639.
122. Tsuruda KM, Bhargava S, Mangerud G, Sagstad S, Hofvind SSH. Monthly variation in mammographic screening attendance in Norway. *European journal of public health.* 2017:ckx137.
123. Moshina N, Sebuodegard S, Hofvind S. Is breast compression associated with breast cancer detection and other early performance measures in a population-based breast cancer screening program? *Breast Cancer Res Treat.* 2017;163(3):605-13.
124. Jørgensen KJ, Kalager M, Barratt A, Baines C, Zahl PH, Brodersen J, et al. Overview of guidelines on breast screening: Why recommendations differ and what to do about it. *The Breast.* 2017;31:261-9.
125. Ellingjord-Dale M, Vos L, Hjerkind KV, Hjartaker A, Russnes HG, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G. Alcohol, Physical Activity, Smoking, and Breast Cancer Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer Screening Program. *Cancer Epidemiol Biomarkers Prev.* 2017 Dec;26(12):1736-1744.
126. Vikestad KG, Hafskjold L, Kjelle E, Sebuødegård S, Hofvind S. Radiographers' opinions on radiography research in Norway - A national survey. *Radiography (Lond).* 2017 May;23(2):135-140.
127. Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. *Breast Cancer Res.* 2017 Jan 23;19(1):10.
128. Østerås BH, Martinsen AC, Brandal SH, Chaudhry KN, Eben E, Haakenaasen U, et al. BI-RADS Density Classification From Areometric and Volumetric Automatic Breast Density Measurements. *Acad Radiol.* 2016;23(4):468-78.
129. Østerås BH, Martinsen AC, Brandal SH, Chaudhry KN, Eben E, Haakenaasen U, et al. Classification of fatty and dense breast parenchyma: comparison of automatic volumetric density measurement and radiologists' classification and their inter-observer variation. *Acta radiologica (Stockholm, Sweden : 1987).* 2016;57(10):1178-85.
130. Waade GG, Highnam R, Hauge IH, McEntee MF, Hofvind S, Denton E, et al. Impact of errors in recorded compressed breast thickness measurements on volumetric density classification using volpara v1.5.0 software. *Med Phys.* 2016;43(6):2870.
131. Sebuødegård S, Sagstad S, Hofvind S. [Attendance in the Norwegian Breast Cancer Screening Programme]. *Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.* 2016;136(17):1448-51.

132. Sardanelli F, Aase HS, Alvarez M, Azavedo E, Baarslag HJ, Balleyguier C, et al. Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey. *Eur Radiol.* 2016.
133. Roman M, Sakshaug S, Graff-Iversen S, Vangen S, Weiderpass E, Ursin G, et al. Postmenopausal hormone therapy and the risk of breast cancer in Norway. *Int J Cancer.* 2016;138(3):584-93.
134. Roman M, Graff-Iversen S, Weiderpass E, Vangen S, Sakshaug S, Hofvind S, et al. Postmenopausal Hormone Therapy and Breast Cancer Prognostic Characteristics: A Linkage between Nationwide Registries. *Cancer Epidemiol Biomarkers Prev.* 2016;25(11):1464-73.
135. Roman M, Castells X, Hofvind S, von Euler-Chelpin M. Risk of breast cancer after false-positive results in mammographic screening. *Cancer Med.* 2016;5(6):1298-306.
136. Moshina N, Ursin G, Roman M, Sebuødegård S, Hofvind S. Positive predictive values by mammographic density and screening mode in the Norwegian Breast Cancer Screening Program. *Eur J Radiol.* 2016;85(1):248-54.
137. Moger TA, Bjørnelv GM, Aas E. Expected 10-year treatment cost of breast cancer detected within and outside a public screening program in Norway. *The European journal of health economics : HEPAC : health economics in prevention and care.* 2016;17(6):745-54.
138. Michalopoulos D, Duffy SW. Estimation of overdiagnosis using short-term trends and lead time estimates uncontaminated by overdiagnosed cases: Results from the Norwegian Breast Screening Programme. *J Med Screen.* 2016;23(4):192-202.
139. Lesurf R, Aure MR, Mork HH, Vitelli V, Oslo Breast Cancer Research Consortium, Lundgren S, et al. Molecular features of subtype-specific progression from ductal carcinoma in situ to invasive breast cancer. *Cell reports.* 2016;16(4):1166-79.
140. Houssami N, Lang K, Bernardi D, Tagliafico A, Zackrisson S, Skaane P. Digital breast tomosynthesis (3D-mammography) screening: A pictorial review of screen-detected cancers and false recalls attributed to tomosynthesis in prospective screening trials. *Breast.* 2016;26:119-34.
141. Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Erika Y, Körner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F; Oslo Breast Cancer Research Consortium (OSBREAC) SauerTorill GeislerJürgen HofvindSolweig BathenToneF BorgenElin EngebråtenOlav FodstadØystein GarredØystein GeitvikGryAarum KåresenRolf NaumeBjørn MælandsmoGunhild MariRussnes Hege G SchlichtingEllen SørliTherese LingjærdeOle Christian SahlbergKristine Kleivi SkjervenHelle KristineFritzman Britt; Ulitsky I, Diederichs S, Wiemann S, Yakhini Z, Kristensen VN, Børresen-Dale AL, Yarden Y. LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. *EMBO Mol Med.* 2016 Sep 1;8(9):1052-64.
142. Hofvind S, Roman M, Sebuødegård S, Falk RS. Balancing the benefits and detriments among women targeted by the Norwegian Breast Cancer Screening Program. *J Med Screen.* 2016;23(4):203-9.
143. Hofvind S, Holen Å, Roman M, Sebuødegård S, Puig-Vives M, Aksten L. Mode of detection: an independent prognostic factor for women with breast cancer. *J Med Screen.* 2016;23(2):89-97.
144. Hofvind S, Bennett RL, Brisson J, Lee W, Pelletier E, Flugelman A, et al. Audit feedback on reading performance of screening mammograms: An international comparison. *J Med Screen.* 2016;23(3):150-9.
145. Falk RS, Hofvind S. Overdiagnosis in Mammographic Screening because of Competing Risk of Death. *Cancer Epidemiol Biomarkers Prev.* 2016;25(5):759-65.
146. Domingo L, Hofvind S, Hubbard RA, Roman M, Benkeser D, Sala M, et al. Cross-national comparison of screening mammography accuracy measures in U.S., Norway, and Spain. *Eur Radiol.* 2016;26(8):2520-8.
147. Deandrea S, Molina-Barcelo A, Uluturk A, Moreno J, Neamtii L, Peiro-Perez R, et al. Presence, characteristics and equity of access to breast cancer screening programmes in 27 European countries in 2010 and 2014. Results from an international survey. *Preventive medicine.* 2016;91:250-63.
148. Zahl PH, Maehlen J. Bias in observational studies of the association between menopausal hormone therapy and breast cancer. *PLoS One.* 2015;10(5):e0124076.
149. Suhrke P, Zahl PH. Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study. *Cancer Med.* 2015;4(8):1303-8.
150. Solbjør M, Skolbekken JA, Østerlie W, Forsmo S. Women's experiences with mammography screening through 6 years of participation--a longitudinal qualitative study. *Health care for women international.* 2015;36(5):558-77.

151. Skaane P, Gullien R, Eben EB, Sandhaug M, Schulz-Wendtland R, Stoeblen F. Interpretation of automated breast ultrasound (ABUS) with and without knowledge of mammography: a reader performance study. *Acta radiologica* (Stockholm, Sweden : 1987). 2015;56(4):404-12.
152. Moshina N, Ursin G, Hoff SR, Akslen LA, Roman M, Sebuødegård S, et al. Mammographic density and histopathologic characteristics of screen-detected tumors in the Norwegian Breast Cancer Screening Program. *Acta Radiol Open*. 2015;4(9):2058460115604340.
153. Løberg M, Lousdal ML, Bretthauer M, Kalager M. Benefits and harms of mammography screening. *Breast Cancer Res*. 2015;17:63.
154. Hofvind S, Holen Å, Aas T, Roman M, Sebuødegård S, Akslen LA. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics. *Eur J Surg Oncol*. 2015;41(10):1417-22.
155. Ellingjord-Dale M, dos-Santos-Silva I, Grotmol T, Sakhi AK, Hofvind S, Qureshi S, et al. Vitamin D intake, month the mammogram was taken and mammographic density in Norwegian women aged 50-69. *PLoS One*. 2015;10(5):e0123754.
156. Boyce M, Gullien R, Parashar D, Taylor K. Comparing the use and interpretation of PGMI scoring to assess the technical quality of screening mammograms in the UK and Norway. *Radiography*. 2015;21(4):342-7.
157. Zahl PH, Jorgensen KJ, Gotzsche PC. Lead-time models should not be used to estimate overdiagnosis in cancer screening. *Journal of general internal medicine*. 2014;29(9):1283-6.
158. Weedon-Fekjaer H, Romundstad PR, Vatten LJ. Modern mammography screening and breast cancer mortality: population study. *BMJ*. 2014;348:g3701.
159. Skaane P, Bandos AI, Eben EB, Jepsen IN, Krager M, Haakenaasen U, et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. *Radiology*. 2014;271(3):655-63.
160. Roman M, Skaane P, Hofvind S. The cumulative risk of false-positive screening results across screening centres in the Norwegian Breast Cancer Screening Program. *Eur J Radiol*. 2014;83(9):1639-44.
161. Qureshi SA, Lund AC, Veierod MB, Carlsen MH, Blomhoff R, Andersen LF, et al. Food items contributing most to variation in antioxidant intake; a cross-sectional study among Norwegian women. *BMC Public Health*. 2014;14(1):45.
162. Ponti A, Lynge E, James T, Majek O, von Euler-Chelpin M, Anttila A, et al. International variation in management of screen-detected ductal carcinoma in situ of the breast. *Eur J Cancer*. 2014;50(15):2695-704.
163. Paci E, Broeders M, Hofvind S, Puliti D, Duffy SW, EUROSREEN Working Group. European breast cancer service screening outcomes: a first balance sheet of the benefits and harms. *Cancer Epidemiol Biomarkers Prev*. 2014;23(7):1159-63.
164. Lynge E, Ponti A, James T, Majek O, von Euler-Chelpin M, Anttila A, et al. Variation in detection of ductal carcinoma in situ during screening mammography: a survey within the International Cancer Screening Network. *Eur J Cancer*. 2014;50(1):185-92.
165. Lousdal ML, Kristiansen IS, Moller B, Stovring H. Trends in breast cancer stage distribution before, during and after introduction of a screening programme in Norway. *European journal of public health*. 2014;24(6):1017-22.
166. Kalager M, Loberg M, Bretthauer M, Adami HO. Comparative analysis of breast cancer mortality following mammography screening in Denmark and Norway. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2014;25(6):1137-43.
167. Hofvind S, Skaane P, Elmore JG, Sebuødegård S, Hoff SR, Lee CI. Mammographic performance in a population-based screening program: before, during, and after the transition from screen-film to full-field digital mammography. *Radiology*. 2014;272(1):52-62.
168. Hauge IH, Pedersen K, Olerud HM, Hole EO, Hofvind S. The risk of radiation-induced breast cancers due to biennial mammographic screening in women aged 50-69 years is minimal. *Acta radiologica* (Stockholm, Sweden : 1987). 2014;55(10):1174-9.
169. Duffy SW, Michalopoulos D, Sebuødegård S, Hofvind S. Trends in aggregate cancer incidence rates in relation to screening and possible overdiagnosis: a word of caution. *J Med Screen*. 2014;21(1):24-9.
170. Chen Y, Klingens TA, Wik E, Aas H, Vigeland E, Liestol K, et al. Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study. *Diagnostic pathology*. 2014;9:230.
171. Zahl PH, Jorgensen KJ, Gotzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. *Br J Cancer*. 2013;109(7):2014-9.

172. Ellingjord-Dale M, Grotmol T, Lee E, Van Den Berg DJ, Hofvind S, Couto E, Sovio U, Dos-Santos-Silva I, Ursin G. Breast cancer susceptibility variants and mammographic density phenotypes in norwegian postmenopausal women. *Cancer Epidemiol Biomarkers Prev.* 2014 Sep;23(9):1752-63.
173. Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. *Radiology.* 2013;267(1):47-56.
174. Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, et al. Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration. *Eur Radiol.* 2013;23(8):2061-71.
175. Schou Bredal I, Karesen R, Skaane P, Engelstad KS, Ekeberg O. Recall mammography and psychological distress. *Eur J Cancer.* 2013;49(4):805-11.
176. Roman M, Hubbard RA, Sebuødegård S, Miglioretti DL, Castells X, Hofvind S. The cumulative risk of false-positive results in the Norwegian Breast Cancer Screening Program: updated results. *Cancer.* 2013;119(22):3952-8.
177. Olsen AH, Lynge E, Njor SH, Kumle M, Waaseth M, Braaten T, et al. Breast cancer mortality in Norway after the introduction of mammography screening. *Int J Cancer.* 2013;132(1):208-14.
178. Lund E, Mode N, Waaseth M, Thalabard JC. Overdiagnosis of breast cancer in the Norwegian Breast Cancer Screening Program estimated by the Norwegian Women and Cancer cohort study. *BMC Cancer.* 2013;13:614.
179. Houssami N, Skaane P. Overview of the evidence on digital breast tomosynthesis in breast cancer detection. *Breast.* 2013;22(2):101-8.
180. Hofvind S, Ursin G, Tretli S, Sebuødegård S, Moller B. Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. *Cancer.* 2013;119(17):3106-12.
181. Hofvind S, Schlichting E, Ursin G, S. S, Karesen R. [Breast cancer surgery in Norway 1986-2009]. *Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.* 2013;133(15):1582-6.
182. Hoff SR, Klepp O, Hofvind S. Asymptomatic breast cancer in non-participants of the national screening-programme in Norway: a confounding factor in evaluation? *J Med Screen.* 2013;19(4):177-83.
183. Hauge IH, Olerud HM. Uncertainties involved in the estimation of mean glandular dose for women in the Norwegian Breast Cancer Screening Program (NBCSP). *Radiat Prot Dosimetry.* 2013;155(1):81-7.
184. Falk RS, Hofvind S, Skaane P, Haldorsen T. Overdiagnosis among women attending a population-based mammography screening program. *Int J Cancer.* 2013;133(3):705-12.
185. Zahl PH, Maehlen J. Overdiagnostikk av brystkreft etter 14 år med mammografiscreening = Overdiagnosis of breast cancer after 14 years of mammography screening. *Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.* 2012;132(4):414-7.
186. Weedon-Fekjaer H, Bakken K, Vatten LJ, Tretli S. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. *BMJ.* 2012;344:e299.
187. Suhrke P, Maehlen J, Zahl PH. Hormone therapy use and breast cancer incidence by histological subtypes in Sweden and Norway. *The breast journal.* 2012;18(6):549-56.
188. Solbjør M, Skolbekken JA, Saetnan AR, Hagen AI, Forsmo S. Mammography screening and trust: the case of interval breast cancer. *Soc Sci Med.* 2012;75(10):1746-52.
189. Solbjør M, Skolbekken JA, Saetnan AR, Hagen AI, Forsmo S. Could screening participation bias symptom interpretation? An interview study on women's interpretations of and responses to cancer symptoms between mammography screening rounds. *BMJ Open.* 2012;2(6).
190. Skaane P, Kshirsagar A, Hofvind S, Jahr G, Castellino RA. Mammography screening using independent double reading with consensus: is there a potential benefit for computer-aided detection? *Acta radiologica (Stockholm, Sweden : 1987).* 2012;53(3):241-8.
191. Qureshi SA, Ellingjord-Dale M, Hofvind S, Wu AH, Ursin G. Physical activity and mammographic density in a cohort of postmenopausal Norwegian women; a cross-sectional study. *SpringerPlus.* 2012;1(1):75.
192. Qureshi SA, Couto E, Hofvind S, Wu AH, Ursin G. Alcohol intake and mammographic density in postmenopausal Norwegian women. *Breast Cancer Res Treat.* 2012;131(3):993-1002.
193. Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. *J Med Screen.* 2012;19 Suppl 1:42-56.
194. Paci E, EUROSCREEN Working Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. *J Med Screen.* 2012;19 Suppl 1:5-13.

195. Norum J, Hofvind S, Nieder C, Schnell EA, Broderstad AR. Mammographic screening in Sami speaking municipalities and a control group. Are early outcome measures influenced by ethnicity? *International journal of circumpolar health*. 2012;71:1-6.
196. Njor S, Nystrom L, Moss S, Paci E, Broeders M, Segnan N, et al. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. *J Med Screen*. 2012;19 Suppl 1:33-41.
197. Moss SM, Nystrom L, Jonsson H, Paci E, Lynge E, Njor S, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of trend studies. *J Med Screen*. 2012;19 Suppl 1:26-32.
198. Kalager M, Tamimi RM, Bretthauer M, Adami HO. Prognosis in women with interval breast cancer: population based observational cohort study. *BMJ*. 2012;345:e7536.
199. Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. *Annals of internal medicine*. 2012;156(7):491-9.
200. Hofvind S, Skaane P. Stage distribution of breast cancer diagnosed before and after implementation of population-based mammographic screening. *RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin*. 2012;184(5):437-42.
201. Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway--explained by hormone therapy or mammographic screening? *Int J Cancer*. 2012;130(12):2930-8.
202. Hofvind S, Ponti A, Patnick J, Ascunce N, Njor S, Broeders M, et al. False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. *J Med Screen*. 2012;19 Suppl 1:57-66.
203. Hofvind S, Lee CI, Elmore JG. Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program. *Breast Cancer Res Treat*. 2012;135(1):291-9.
204. Hofvind S, Geller BM, Skelly J, Vacek PM. Sensitivity and specificity of mammographic screening as practised in Vermont and Norway. *Br J Radiol*. 2012;85(1020):e1226-32.
205. Hoff SR, Abrahamsen AL, Samset JH, Vigeland E, Klepp O, Hofvind S. Breast cancer: missed interval and screening-detected cancer at full-field digital mammography and screen-film mammography-- results from a retrospective review. *Radiology*. 2012;264(2):378-86.
206. Hauge IH, Pedersen K, Sanderud A, Hofvind S, Olerud HM. Patient doses from screen-film and full-field digital mammography in a population-based screening programme. *Radiat Prot Dosimetry*. 2012;148(1):65-73.
207. Hansen BT, Nygard M, Falk RS, Hofvind S. Breast cancer and ductal carcinoma in situ among women with prior squamous or glandular precancer in the cervix: a register-based study. *Br J Cancer*. 2012;107(9):1451-3.
208. Hafslund B, Espehaug B, Nortvedt MW. Effects of false-positive results in a breast screening program on anxiety, depression and health-related quality of life. *Cancer Nurs*. 2012;35(5):E26-34.
209. Hafslund B, Espehaug B, Nortvedt MW. Health-related quality of life, anxiety and depression related to mammography screening in Norway. *J Clin Nurs*. 2012;21(21-22):3223-34.
210. Giordano L, von Karsa L, Tomatis M, Majek O, de Wolf C, Lancucki L, et al. Mammographic screening programmes in Europe: organization, coverage and participation. *J Med Screen*. 2012;19 Suppl 1(1_suppl):72-82.
211. Giordano L, Cogo C, Patnick J, Paci E, Euroscreen Working Group. Communicating the balance sheet in breast cancer screening. *J Med Screen*. 2012;19 Suppl 1:67-71.
212. Ellingjord-Dale M, Lee E, Couto E, Ozhand A, Qureshi S, Hofvind S, et al. Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users. *Breast Cancer Res*. 2012;14(5):R135.
213. Couto E, Qureshi SA, Hofvind S, Hilsen M, Aase H, Skaane P, et al. Hormone therapy use and mammographic density in postmenopausal Norwegian women. *Breast Cancer Res Treat*. 2012;132(1):297-305.
214. Broeders M, Moss S, Nystrom L, Njor S, Jonsson H, Paap E, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. *J Med Screen*. 2012;19 Suppl 1:14-25.
215. Suhrke P, Maehlen J, Schlichting E, Jorgensen KJ, Gotzsche PC, Zahl PH. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ*. 2011;343:d4692.
216. Solbjør M, Forsmo S, Skolbekken JA, Saetnan AR. Experiences of recall after mammography screening--a qualitative study. *Health care for women international*. 2011;32(11):1009-27.
217. Qureshi SA, Couto E, Hilsen M, Hofvind S, Wu AH, Ursin G. Mammographic density and intake of selected nutrients and vitamins in Norwegian women. *Nutr Cancer*. 2011;63(7):1011-20.
218. Lynge E, Braaten T, Njor SH, Olsen AH, Kumle M, Waaseth M, et al. Mammography activity in Norway 1983 to 2008. *Acta Oncol*. 2011;50(7):1062-7.

219. Hofvind S, Iversen BF, Eriksen L, Styr BM, Kjellevoid K, Kurz KD. Mammographic morphology and distribution of calcifications in ductal carcinoma in situ diagnosed in organized screening. *Acta radiologica (Stockholm, Sweden : 1987)*. 2011;52(5):481-7.
220. Hoff SR, Samset JH, Abrahamsen AL, Vigeland E, Klepp O, Hofvind S. Missed and true interval and screen-detected breast cancers in a population based screening program. *Acad Radiol*. 2011;18(4):454-60.
221. Falk RS, Hofvind S, Skaane P, Haldorsen T. Second events following ductal carcinoma in situ of the breast: a register-based cohort study. *Breast Cancer Res Treat*. 2011;129(3):929-38.
222. Weedon-Fekjaer H, Tretli S, Aalen OO. Estimating screening test sensitivity and tumour progression using tumour size and time since previous screening. *Statistical methods in medical research*. 2010;19(5):507-27.
223. Tornberg S, Kemetli L, Ascunce N, Hofvind S, Anttila A, Seradour B, et al. A pooled analysis of interval cancer rates in six European countries. *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)*. 2010;19(2):87-93.
224. Sørnum R, Hofvind S, Skaane P, Haldorsen T. Trends in incidence of ductal carcinoma in situ: the effect of a population-based screening programme. *The Breast*. 2010;19(6):499-505.
225. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. *The New England journal of medicine*. 2010;363(13):1203-10.
226. Juel IM, Skaane P, Hoff SR, Johannessen G, Hofvind S. Screen-film mammography versus full-field digital mammography in a population-based screening program: The Sogn and Fjordane study. *Acta radiologica (Stockholm, Sweden : 1987)*. 2010;51(9):962-8.
227. Dowling EC, Klabunde C, Patnick J, Ballard-Barbash R, International Cancer Screening N. Breast and cervical cancer screening programme implementation in 16 countries. *J Med Screen*. 2010;17(3):139-46.
228. Wang H, Jepsen PW, Kåresen R, Thoresen S. Ductal Carcinoma In Situ of the Breast: A Review of Diagnosis, Treatment and Outcome in a Hospital-based Norwegian Series. *Acta Oncologica*. 2009;39(2):131-4.
229. Stuedal A, Ma H, Bjørndal H, Ursin G. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. *Climacteric : the journal of the International Menopause Society*. 2009;12(3):248-58.
230. Skaane P. Studies comparing screen-film mammography and full-field digital mammography in breast cancer screening: updated review. *Acta radiologica (Stockholm, Sweden : 1987)*. 2009;50(1):3-14.
231. Pedersen K, Landmark ID. Trial of a proposed protocol for constancy control of digital mammography systems. *Med Phys*. 2009;36(12):5537-46.
232. Myklebust A, Seierstad T, Strandén E, Lerdal A. Level of satisfaction during mammography screening in relation to discomfort, service provided, level of pain and breast compression. *Eur J Radiography*. 2009;1(2):66-72.
233. Kalager M, Karesen R, Wist E. [Survival after breast cancer--differences between Norwegian counties]. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny raekke*. 2009;129(24):2595-600.
234. Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO. Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study. *Breast Cancer Res*. 2009;11(4):R44.
235. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. *BMJ*. 2009;339.
236. Hofvind S, Yankaskas BC, Bulliard JL, Klabunde CN, Fracheboud J. Comparing interval breast cancer rates in Norway and North Carolina: results and challenges. *J Med Screen*. 2009;16(3):131-9.
237. Hofvind S, Vee B, Sørnum R, Hauge M, Ertzaas AK. Quality assurance of mammograms in the Norwegian Breast Cancer Screening Program. *Eur J Radiography*. 2009;1(1):22-9.
238. Hofvind S, Geller BM, Rosenberg RD, Skaane P. Screening-detected breast cancers: discordant independent double reading in a population-based screening program. *Radiology*. 2009;253(3):652-60.
239. Østerlie W, Solbjør M, Skolbekken JA, Hofvind S, Saetnan AR, Forsmo S. Challenges of informed choice in organised screening. *Journal of medical ethics*. 2008;34(9):e5.
240. Zahl PH, Maehlen J, Welch HG. The natural history of invasive breast cancers detected by screening mammography. *Arch Intern Med*. 2008;168(21):2311-6.
241. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S. Breast cancer tumor growth estimated through mammography screening data. *Breast Cancer Res*. 2008;10(3):R41.
242. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S. Estimating mean sojourn time and screening sensitivity using questionnaire data on time since previous screening. *J Med Screen*. 2008;15(2):83-90.

243. Vigeland E, Klaasen H, Klingen TA, Hofvind S, Skaane P. Full-field digital mammography compared to screen film mammography in the prevalent round of a population-based screening programme: the Vestfold County Study. *Eur Radiol.* 2008;18(1):183-91.
244. Skaane P, Diekmann F, Balleyguier C, Diekmann S, Pigué JC, Young K, et al. Observer variability in screen-film mammography versus full-field digital mammography with soft-copy reading. *Eur Radiol.* 2008;18(6):1134-43.
245. Sauer T, Karimzadeh M. Characteristic cytological features of histological grade one (G1) breast carcinomas in fine needle aspirates. *Cytopathology : official journal of the British Society for Clinical Cytology.* 2008;19(5):287-93.
246. Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM. Comparing screening mammography for early breast cancer detection in Vermont and Norway. *J Natl Cancer Inst.* 2008;100(15):1082-91.
247. Hofvind S, Sorum R, Thoresen S. Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. *Acta Oncol.* 2008;47(2):225-31.
248. Hofvind S, Geller B, Skaane P. Mammographic features and histopathological findings of interval breast cancers. *Acta radiologica (Stockholm, Sweden : 1987).* 2008;49(9):975-81.
249. Gram IT, Lund E. Breast cancer screening programme as setting for an adjunct research project: effect on programme attendance. *J Med Screen.* 2008;15(1):44-5.
250. Skaane P, Kshirsagar A, Stapleton S, Young K, Castellino RA. Effect of computer-aided detection on independent double reading of paired screen-film and full-field digital screening mammograms. *AJR American journal of roentgenology.* 2007;188(2):377-84.
251. Skaane P, Hofvind S, Skjennald A. Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population-based screening program: follow-up and final results of Oslo II study. *Radiology.* 2007;244(3):708-17.
252. Hofvind S, Geller B, Vacek PM, Thoresen S, Skaane P. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. *Eur J Epidemiol.* 2007;22(7):447-55.
253. Hofvind S. Breast cancer screening--prevalence of disease in women who only respond after an invitation reminder. *J Med Screen.* 2007;14(1):21-2.
254. Geller BM, Zapka J, Hofvind SSH, Scharpantgen A, Giordano L, Ohuchi N, et al. Communicating with women about mammography. *Journal of Cancer Education.* 2007;22(1):25-31.
255. Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT. Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. *Int J Cancer.* 2007;121(11):2506-11.
256. Bremnes Y, Ursin G, Bjurstam N, Gram IT. Different measures of smoking exposure and mammographic density in postmenopausal Norwegian women: a cross-sectional study. *Breast Cancer Res.* 2007;9(5):R73.
257. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. *The New England journal of medicine.* 2007;356(3):227-36.
258. Tornberg S, Kemetli L, Lyng E, Helene Olsen A, Hofvind S, Wang H, et al. Breast cancer incidence and mortality in the Nordic capitals, 1970-1998. Trends related to mammography screening programmes. *Acta Oncol.* 2006;45(5):528-35.
259. Hofvind S, Sorum R, Haldorsen T, Langmark F. [Incidence of breast cancer before and after implementation of mammography screening]. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række.* 2006;126(22):2935-8.
260. Hofvind S, Møller B, Thoresen S, Ursin G. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. *Int J Cancer.* 2006;118(12):3112-7.
261. Hofvind S, Huber T, Sørsum R, et al. Utforming, testing, prosedyrer og anbefalinger ved innføring av nytt spørreskjema i mammografiprogrammet. 2006.
262. Hofvind S, Bjurstam N, Sorum R, Bjorndal H, Thoresen S, Skaane P. Number and characteristics of breast cancer cases diagnosed in four periods in the screening interval of a biennial population-based screening programme. *J Med Screen.* 2006;13(4):192-6.
263. Bremnes Y, Ursin G, Bjurstam N, Lund E, Gram IT. Different types of postmenopausal hormone therapy and mammographic density in Norwegian women. *Int J Cancer.* 2006;120(4):880-4.
264. Weedon-Fekjaer H, Vatten LJ, Aalen OO, Lindqvist B, Tretli S. Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results. *J Med Screen.* 2005;12(4):172-8.
265. Skaane P, Skjennald A, Young K, Egge E, Jepsen I, Sager EM, et al. Follow-up and Final Results of the Oslo I Study Comparing Screen-Film Mammography and Full-field Digital Mammography with Soft-Copy Reading. *Acta radiologica (Stockholm, Sweden : 1987).* 2005;46(7):679-89.

266. Skaane P, Balleyguier C, Diekmann F, Diekmann S, Pigué JC, Young K, et al. Breast lesion detection and classification: comparison of screen-film mammography and full-field digital mammography with soft-copy reading--observer performance study. *Radiology*. 2005;237(1):37-44.
267. Møller B, Weedon-Fekjaer H, Hakulinen T, Tryggvadóttir L, Storm HH, Talback M, et al. The influence of mammographic screening on national trends in breast cancer incidence. *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)*. 2005;14(2):117-28.
268. Hofvind S, Skaane P, Vitak B, Wang H, Thoresen S, Eriksen L, et al. Influence of review design on percentages of missed interval breast cancers: retrospective study of interval cancers in a population-based screening program. *Radiology*. 2005;237(2):437-43.
269. Gram IT, Bremnes Y, Ursin G, Maskarinec G, Bjurstam N, Lund E. Percentage density, Wolfe's and Tabar's mammographic patterns: agreement and association with risk factors for breast cancer. *Breast Cancer Res*. 2005;7(5):R854-61.
270. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. *Cancer Epidemiol Biomarkers Prev*. 2005;14(5):1108-12.
271. Skaane P, Skjennald A. Screen-film mammography versus full-field digital mammography with soft-copy reading: randomized trial in a population-based screening program--the Oslo II Study. *Radiology*. 2004;232(1):197-204.
272. Hofvind S, Wang H, Thoresen S. Do the results of the process indicators in the Norwegian breast cancer screening program predict future mortality reduction from breast cancer? *Acta Oncol*. 2004;43(5):467-73.
273. Hofvind S, Thoresen S, Tretli S. The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. *Cancer*. 2004;101(7):1501-7.
274. Skaane P, Young K, Skjennald A. Population-based mammography screening: comparison of screen-film and full-field digital mammography with soft-copy reading--Oslo I study. *Radiology*. 2003;229(3):877-84.
275. Sauer T, Myrvold K, Lomo J, Anderssen KY, Skaane P. Fine-needle aspiration cytology in nonpalpable mammographic abnormalities in breast cancer screening: results from the breast cancer screening programme in Oslo 1996-2001. *Breast*. 2003;12(5):314-9.
276. Obenauer S, Hermann K-P, Marten K, Luftner-Nagel S, von Heyden D, Skaane P, et al. Soft Copy versus Hard Copy Reading in Digital Mammography. *Journal of Digital Imaging*. 2003;16(4):341-4.
277. Hofvind SS, Wang H, Thoresen S. The Norwegian Breast Cancer Screening Program: re-attendance related to the women's experiences, intentions and previous screening result. *Cancer Causes Control*. 2003;14(4):391-8.
278. Sauer T, Young K, Thoresen SO. Fine needle aspiration cytology in the work-up of mammographic and ultrasonographic findings in breast cancer screening: an attempt at differentiating in situ and invasive carcinoma. *Cytopathology : official journal of the British Society for Clinical Cytology*. 2002;13(2):101-10.
279. Pedersen K, Nordanger J. Quality control of the physical and technical aspects of mammography in the Norwegian breast-screening programme. *Eur Radiol*. 2002;12(2):463-70.
280. Klabunde CN, Sancho-Garnier H, Taplin S, Thoresen S, Ohuchi N, Ballard-Barbash R, et al. Quality assurance in follow-up and initial treatment for screening mammography programs in 22 countries. *Int J Qual Health Care*. 2002;14(6):449-61.
281. Wang H, Karesen R, Hervik A, Thoresen SO. Mammography screening in Norway: results from the first screening round in four counties and cost-effectiveness of a modeled nationwide screening. *Cancer Causes Control*. 2001;12(1):39-45.
282. Wang H, Bjurstam N, Bjørndal H, Braaten A, Eriksen L, Skaane P, et al. Interval cancers in the Norwegian breast cancer screening program: frequency, characteristics and use of HRT. *Int J Cancer*. 2001;94(4):594-8.
283. Klabunde CN, Sancho-Garnier H, Broeders M, Thoresen S, Rodrigues VJ, Ballard-Barbash R. Quality assurance for screening mammography data collection systems in 22 countries. *International journal of technology assessment in health care*. 2001;17(4):528-41.
284. Hofvind SS, Thoresen SO. [Physical activity and breast cancer]. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række*. 2001;121(16):1892-5.
285. Ekeberg Ø, Skjauff H, Kåresen R. Screening for breast cancer is associated with a low degree of psychological distress. *The Breast*. 2001;10(1):20-4.
286. Wang H, Hofvind SS, Thoresen SO. [A pilot project with mammography--results from the first screening round]. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række*. 2000;120(27):3237-40.
287. Thoresen SO. [Mammography screening of women aged 40 plus--how long must the Norwegian women wait this time?]. *Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række*. 1999;119(24):3636.

288. Karesen R, Bo JK, Haustveit S, Hervik A, Thoresen SO. [Cost-effectiveness of mammography screening in Norway]. Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række. 1999;119(24):3553-9.
289. Wang H, Thoresen SO, Tretli S. Breast cancer in Norway 1970-1993: a population-based study on incidence, mortality and survival. Br J Cancer. 1998;77(9):1519-24.
290. Thoresen SØ. Prøveprosjekt med mammografiscreening i fire fylker; organisering og gjennomføring. [Mammography screening in four Norwegian counties: a pilot project]. Nor J Epidemiol. 1997;7(2):179-82.
291. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. Jama. 1996;276(1):33-8.